MiniMed Smart MDI trial links higher alert response to 8.1%-point Time in Range gain, 0.6%-point HbA1c drop

• MiniMed presented six-month randomized trial results showing better glucose control when users responded more often to Smart MDI alerts.
• Higher alert engagement linked to improved day-to-day control versus lower engagement among people using the connected insulin pen system.
• Real-world analysis of more than 5,500 users also tied frequent alert responses to better glucose control, supporting the trial signal.
• Safety profile was clean in the Smart MDI arm, with no severe hypoglycemia or diabetic ketoacidosis reported during the study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MiniMed Group Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA62840) on October 05, 2026, and is solely responsible for the information contained therein.